<DOC>
	<DOC>NCT00361127</DOC>
	<brief_summary>In patients with chronic heart failure ACE-inhibitor treatment improves lung diffusion and prevents pulmonary edema after fluid overload. In the western country, 3 population types of ACE genotypes exist (DD, ID, II). It is unknown whether the ACE genotype influences the response to fluid overload in ACE-inhibitor treated chronic heart failure patients.</brief_summary>
	<brief_title>Influence of Angiotensin Converting Enzyme (ACE) Genotype on Lung Diffusion in Heart Failure</brief_title>
	<detailed_description>Patients with chronic heart failure in stable clinical condition treated with ACE-inhibitors, but not aspirin, will be evaluated by means of maximal cardiopulmonary exercise test and lung function including lung diffusion measurements. These tests will be done before and after rapid 500 ml isotonic saline infusion. Patients will be grouped according to their ACE genotype.</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Angiotensin-Converting Enzyme Inhibitors</mesh_term>
	<criteria>New York Heart Association (NYHA) class I and II heart failure Chronic ACEinhibitor treatment Aspirin treatment in the previous 2 months</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Heart failure</keyword>
	<keyword>pulmonary edema</keyword>
	<keyword>ACE-inhibitors</keyword>
	<keyword>lung diffusion</keyword>
	<keyword>exercise capacity</keyword>
	<keyword>Chronic heart failure</keyword>
</DOC>